Furthermore, promising results demonstrating the efficacy of hypomethylating agents (HMA) in PTCL with mutations in epigenetic regulators (e. g., DNTM3A, TET2, and IDH2) have been obtained in smaller studies (18, 36), raising hope for precise, molecularly tailored treatment regimens. This evidence concerns the gene TET2 and mature T-cell and NK-cell non-Hodgkin lymphoma.